person · Reporting owner

Babler Martin

Disclosed activity across 7 companies

Tapewire entity: 35360
SEC CIK: 0001435618

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ALUMIS INC.ALMS · Entity 4816	Director · President, CEO and Chairman	January 26, 2026	January 29, 2026
MapLight Therapeutics, Inc.MPLT · Entity 5316	Director	June 23, 2026	June 25, 2026
Neurogene Inc.NLTX · Entity 5160	Director	June 08, 2023	June 09, 2023
Omega Alpha SPACOMEG · Entity 143846	Director	January 06, 2021	January 06, 2021
Prelude Therapeutics IncPRLD · Entity 5561	Director	June 09, 2026	June 10, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ALUMIS INC.

Report date January 26, 2026 · Filed January 29, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.31 · Expires 2036-01-25	Direct	745,875	Reported balance After 2026-01-26 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-01-26 · Grant · Acquired 745,875 · Balance 745,875 F1: 25% of the shares underlying this option vest on January 26, 2027, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's Continuous Service (as defined in the Issuer's 2024 Equity Incentive Plan) to the Issuer on each such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: 25% of the shares underlying this option vest on January 26, 2027, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's Continuous Service (as defined in the Issuer's 2024 Equity Incentive Plan) to the Issuer on each such vesting date.

MapLight Therapeutics, Inc.

Report date June 23, 2026 · Filed June 25, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Voting Common StockSEC Table I · non-derivative	Direct	7,864	Reported balance After 2026-06-23 transaction · row 1 1 source row Row 1 · 2026-06-23 · Grant · Acquired 7,864 · Balance 7,864 F1: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2025 Equity Incentive Plan (the "Plan"). The RSUs will vest in three equal annual installments beginning on June 23, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each applicable vesting date. This grant was made pursuant to the Issuer's non-employee director compensation policy. F2: Each RSU represents a contingent right to receive one share of voting common stock of the Issuer.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.64 · Expires 2036-06-22	Direct	29,804	Reported balance After 2026-06-23 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-23 · Grant · Acquired 29,804 · Balance 29,804 F3: Represents a stock option granted pursuant to the Plan. The shares subject to this stock option will vest in three equal annual installments beginning on June 23, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each applicable vesting date. This grant was made pursuant to the Issuer's non-employee director compensation policy.

Filing footnotes · ownership attribution and instrument terms

F1: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2025 Equity Incentive Plan (the "Plan"). The RSUs will vest in three equal annual installments beginning on June 23, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each applicable vesting date. This grant was made pursuant to the Issuer's non-employee director compensation policy.

F2: Each RSU represents a contingent right to receive one share of voting common stock of the Issuer.

F3: Represents a stock option granted pursuant to the Plan. The shares subject to this stock option will vest in three equal annual installments beginning on June 23, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each applicable vesting date. This grant was made pursuant to the Issuer's non-employee director compensation policy.

Neurogene Inc.

Report date June 08, 2023 · Filed June 09, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.79 · Expires 2033-06-07	Direct	25,000	Reported balance After 2023-06-08 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-06-08 · Grant · Acquired 25,000 · Balance 25,000 F1: The option vests as to 1/12 of the total shares monthly beginning July 8, 2023 until the option is fully vested on June 8, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests as to 1/12 of the total shares monthly beginning July 8, 2023 until the option is fully vested on June 8, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Omega Alpha SPAC

Report date January 06, 2021 · Filed January 06, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class B Ordinary SharesSEC Table I · non-derivative	Direct	35,000	Reported balance Holding disclosure · report date 2021-01-06 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 35,000 F1: The Class B Ordinary Shares entitle the holder to one vote for each share held on all matters to be voted on by shareholders and will automatically convert into shares of Class A Ordinary Shares at the time of the Issuer's initial business combination on a one-for-one basis, subject to adjustment, as described in the Issuer's registration statement on Form S-1 (File No. 333-251551). Class B Ordinary Shares have no expiration date.

Filing footnotes · ownership attribution and instrument terms

F1: The Class B Ordinary Shares entitle the holder to one vote for each share held on all matters to be voted on by shareholders and will automatically convert into shares of Class A Ordinary Shares at the time of the Issuer's initial business combination on a one-for-one basis, subject to adjustment, as described in the Issuer's registration statement on Form S-1 (File No. 333-251551). Class B Ordinary Shares have no expiration date.

Prelude Therapeutics Inc

Report date June 09, 2026 · Filed June 10, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.94 · Expires 2036-06-08	Direct	38,000	Reported balance After 2026-06-09 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-09 · Grant · Acquired 38,000 · Balance 38,000 F1: The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date, such to the Reporting Person's provision of service to the Issuer on each vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date, such to the Reporting Person's provision of service to the Issuer on each vesting date.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

89bio, Inc.

Report date October 30, 2025 · Filed October 31, 2025

Section 16 reporting ended · disclosed 2025-10-31. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.86 · Expires 2034-05-02	Direct	0	Reported balance After 2025-10-30 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2025-10-30 · Disposition to issuer · Disposed 67,700 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 17, 2025, by and among 89bio, Inc. (the "Issuer"), Roche Holdings, Inc. ("Parent") and Bluefin Merger Subsidiary, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On October 30, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $14.50 per Share in cash, without interest (the "Closing Amount") less any required withholding taxes, plus (ii) one non-tradeable contingent value right (each, a "CVR") representing the right to receive certain contingent payments of up to an aggregate amount of $6.00 per Share, [continues to Footnote 2] F2: [continues from Footnote 1] in cash, without interest less any required withholding taxes, upon the achievement of specified milestones on or prior to the applicable milestone outside dates, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). F3: As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an "Out of the Money Option"), [continues to Footnote 4] F4: [Continues from Footnote 3] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 5] F5: [Continues from Footnote 4] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.60 · Expires 2035-02-01	Direct	0	Reported balance After 2025-10-30 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2025-10-30 · Disposition to issuer · Disposed 56,400 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 17, 2025, by and among 89bio, Inc. (the "Issuer"), Roche Holdings, Inc. ("Parent") and Bluefin Merger Subsidiary, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On October 30, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $14.50 per Share in cash, without interest (the "Closing Amount") less any required withholding taxes, plus (ii) one non-tradeable contingent value right (each, a "CVR") representing the right to receive certain contingent payments of up to an aggregate amount of $6.00 per Share, [continues to Footnote 2] F2: [continues from Footnote 1] in cash, without interest less any required withholding taxes, upon the achievement of specified milestones on or prior to the applicable milestone outside dates, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). F3: As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an "Out of the Money Option"), [continues to Footnote 4] F4: [Continues from Footnote 3] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 5] F5: [Continues from Footnote 4] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 17, 2025, by and among 89bio, Inc. (the "Issuer"), Roche Holdings, Inc. ("Parent") and Bluefin Merger Subsidiary, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On October 30, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $14.50 per Share in cash, without interest (the "Closing Amount") less any required withholding taxes, plus (ii) one non-tradeable contingent value right (each, a "CVR") representing the right to receive certain contingent payments of up to an aggregate amount of $6.00 per Share, [continues to Footnote 2]

F2: [continues from Footnote 1] in cash, without interest less any required withholding taxes, upon the achievement of specified milestones on or prior to the applicable milestone outside dates, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger").

F3: As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an "Out of the Money Option"), [continues to Footnote 4]

F4: [Continues from Footnote 3] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 5]

F5: [Continues from Footnote 4] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof.

Principia Biopharma Inc.

Report date September 28, 2020 · Filed September 28, 2020

Section 16 reporting ended · disclosed 2020-09-28. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2020-09-28 transaction · row 1 1 source row Row 1 · 2020-09-28 · Other · Disposed 1,023 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the "Issuer"), Sanofi ("Sanofi") and Kortex Acquisition Corp. ("Purchaser") (the "Merger Agreement"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $100.00 per share in cash, without interest and subject to any applicable withholding taxes. F2: Includes 213 shares acquired under the Employment Stock Purchase Plan on September 25, 2020.
Common StockSEC Table I · non-derivative	IndirectSee footnote	Reported balance After 2020-09-28 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2020-09-28 · Other · Disposed 39,179 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the "Issuer"), Sanofi ("Sanofi") and Kortex Acquisition Corp. ("Purchaser") (the "Merger Agreement"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $100.00 per share in cash, without interest and subject to any applicable withholding taxes. F3: Shares indirectly held by Babler Trust Agreement Dated October 25, 2006, of which the Reporting Person is a trustee and may be deemed to share voting and dispositive power over these shares.
Common StockSEC Table I · non-derivative	IndirectSee footnote	Reported balance After 2020-09-28 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2020-09-28 · Other · Disposed 18,355 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the "Issuer"), Sanofi ("Sanofi") and Kortex Acquisition Corp. ("Purchaser") (the "Merger Agreement"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $100.00 per share in cash, without interest and subject to any applicable withholding taxes. F4: Shares indirectly held by Martin Babler, as custodian for his minor children under California Uniform Transfer to Minors Act, of which the Reporting Person is a custodian and may be deemed to share voting and dispositive power over these shares.
Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.99 · Expires 2022-12-29	IndirectSee footnote	Reported balance After 2020-09-28 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-09-28 · Disposition to issuer · Disposed 255 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each warrant was converted into the right to receive $100.00 less the applicable exercise price per share of such warrant. F4: Shares indirectly held by Martin Babler, as custodian for his minor children under California Uniform Transfer to Minors Act, of which the Reporting Person is a custodian and may be deemed to share voting and dispositive power over these shares.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.91 · Expires 2022-07-02	Direct	Reported balance After 2020-09-28 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-09-28 · Disposition to issuer · Disposed 50,795 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.00 · Expires 2023-10-23	Direct	Reported balance After 2020-09-28 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2020-09-28 · Disposition to issuer · Disposed 85,728 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.18 · Expires 2024-06-26	Direct	Reported balance After 2020-09-28 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2020-09-28 · Disposition to issuer · Disposed 110,085 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.72 · Expires 2024-12-25	Direct	Reported balance After 2020-09-28 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2020-09-28 · Disposition to issuer · Disposed 83,004 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.00 · Expires 2025-07-20	Direct	Reported balance After 2020-09-28 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2020-09-28 · Disposition to issuer · Disposed 60,546 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.27 · Expires 2027-12-13	Direct	Reported balance After 2020-09-28 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2020-09-28 · Disposition to issuer · Disposed 115,590 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.35 · Expires 2028-08-23	Direct	Reported balance After 2020-09-28 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2020-09-28 · Disposition to issuer · Disposed 187,144 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.42 · Expires 2029-02-28	Direct	Reported balance After 2020-09-28 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2020-09-28 · Disposition to issuer · Disposed 155,000 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $67.31 · Expires 2030-03-04	Direct	Reported balance After 2020-09-28 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2020-09-28 · Disposition to issuer · Disposed 200,000 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the "Issuer"), Sanofi ("Sanofi") and Kortex Acquisition Corp. ("Purchaser") (the "Merger Agreement"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $100.00 per share in cash, without interest and subject to any applicable withholding taxes.

F2: Includes 213 shares acquired under the Employment Stock Purchase Plan on September 25, 2020.

F3: Shares indirectly held by Babler Trust Agreement Dated October 25, 2006, of which the Reporting Person is a trustee and may be deemed to share voting and dispositive power over these shares.

F4: Shares indirectly held by Martin Babler, as custodian for his minor children under California Uniform Transfer to Minors Act, of which the Reporting Person is a custodian and may be deemed to share voting and dispositive power over these shares.

F5: Pursuant to the Merger Agreement, at the Effective Time, each warrant was converted into the right to receive $100.00 less the applicable exercise price per share of such warrant.

F6: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 23, 2026 Filed Jun 25, 2026 22:01 UTC	MapLight Therapeutics, Inc. MPLT · Entity 5316	GrantStock Option (right to buy) · Derivative	29,804	$0.00 Strike: $28.64	$0.00	Disclosure SEC source: 0001435618-26-000011 · form4-06252026_100631.xml · derivative · entry 2 Babler Martin · CIK 0001435618 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,804 Underlying: Voting Common Stock · 29,804 shares Expires 2036-06-22 F3 · derivative.exercise_date: Represents a stock option granted pursuant to the Plan. The shares subject to this stock option will vest in three equal annual installments beginning on June 23, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each applicable vesting date. This grant was made pursuant to the Issuer's non-employee director compensation policy. Read SEC document
June 23, 2026 Filed Jun 25, 2026 22:01 UTC	MapLight Therapeutics, Inc. MPLT · Entity 5316	GrantVoting Common Stock	7,864	$0.00	$0.00	Disclosure SEC source: 0001435618-26-000011 · form4-06252026_100631.xml · nonDerivative · entry 1 Babler Martin · CIK 0001435618 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,864 F1 · shares: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2025 Equity Incentive Plan (the "Plan"). The RSUs will vest in three equal annual installments beginning on June 23, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each applicable vesting date. This grant was made pursuant to the Issuer's non-employee director compensation policy. F2 · price: Each RSU represents a contingent right to receive one share of voting common stock of the Issuer. Read SEC document
June 09, 2026 Filed Jun 10, 2026 20:15 UTC	Prelude Therapeutics Inc PRLD · Entity 5561	GrantDirector Stock Option (Right to Buy) · Derivative	38,000	$0.00 Strike: $3.94	$0.00	Disclosure SEC source: 0001435618-26-000006 · primarydocument.xml · derivative · entry 1 Babler Martin · CIK 0001435618 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,000 Underlying: Common Stock · 38,000 shares Expires 2036-06-08 F1 · derivative.exercise_date: The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date, such to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
January 26, 2026 Filed Jan 29, 2026 00:21 UTC	ALUMIS INC. ALMS · Entity 4816	GrantStock Option (Right to Buy) · Derivative	745,875	$0.00 Strike: $26.31	$0.00	Disclosure SEC source: 0001435618-26-000003 · form4-01292026_120158.xml · derivative · entry 1 Babler Martin · CIK 0001435618 · Director · President, CEO and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 745,875 Underlying: Common Stock · 745,875 shares Expires 2036-01-25 F1 · derivative.exercise_date: 25% of the shares underlying this option vest on January 26, 2027, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's Continuous Service (as defined in the Issuer's 2024 Equity Incentive Plan) to the Issuer on each such vesting date. Read SEC document
October 30, 2025 Filed Oct 31, 2025 00:14 UTC	89bio, Inc. ETNB · Entity 73682	Disposition to issuerStock Option (Right to Buy) · Derivative	56,400	$0.00 Strike: $9.60	$0.00	Disclosure SEC source: 0001193125-25-259040 · ownership.xml · derivative · entry 2 Babler Martin · CIK 0001435618 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 56,400 shares Expires 2035-02-01 F1 · derivative.exercise_date: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 17, 2025, by and among 89bio, Inc. (the "Issuer"), Roche Holdings, Inc. ("Parent") and Bluefin Merger Subsidiary, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On October 30, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $14.50 per Share in cash, without interest (the "Closing Amount") less any required withholding taxes, plus (ii) one non-tradeable contingent value right (each, a "CVR") representing the right to receive certain contingent payments of up to an aggregate amount of $6.00 per Share, [continues to Footnote 2] F2 · derivative.exercise_date: [continues from Footnote 1] in cash, without interest less any required withholding taxes, upon the achievement of specified milestones on or prior to the applicable milestone outside dates, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). F3 · derivative.exercise_date: As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an "Out of the Money Option"), [continues to Footnote 4] F4 · derivative.exercise_date: [Continues from Footnote 3] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 5] F5 · derivative.exercise_date: [Continues from Footnote 4] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof. Read SEC document
October 30, 2025 Filed Oct 31, 2025 00:14 UTC	89bio, Inc. ETNB · Entity 73682	Disposition to issuerStock Option (Right to Buy) · Derivative	67,700	$0.00 Strike: $8.86	$0.00	Disclosure SEC source: 0001193125-25-259040 · ownership.xml · derivative · entry 1 Babler Martin · CIK 0001435618 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 67,700 shares Expires 2034-05-02 F1 · derivative.exercise_date: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 17, 2025, by and among 89bio, Inc. (the "Issuer"), Roche Holdings, Inc. ("Parent") and Bluefin Merger Subsidiary, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On October 30, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $14.50 per Share in cash, without interest (the "Closing Amount") less any required withholding taxes, plus (ii) one non-tradeable contingent value right (each, a "CVR") representing the right to receive certain contingent payments of up to an aggregate amount of $6.00 per Share, [continues to Footnote 2] F2 · derivative.exercise_date: [continues from Footnote 1] in cash, without interest less any required withholding taxes, upon the achievement of specified milestones on or prior to the applicable milestone outside dates, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). F3 · derivative.exercise_date: As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an "Out of the Money Option"), [continues to Footnote 4] F4 · derivative.exercise_date: [Continues from Footnote 3] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 5] F5 · derivative.exercise_date: [Continues from Footnote 4] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof. Read SEC document
July 29, 2025 Filed Aug 1, 2025 01:05 UTC	ALUMIS INC. ALMS · Entity 4816	GrantStock Option (Right to Buy) · Derivative	150,000	$0.00 Strike: $3.95	$0.00	Disclosure SEC source: 0001415889-25-020801 · form4-07312025_090701.xml · derivative · entry 4 Babler Martin · CIK 0001435618 · Director · President, CEO and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2035-07-28 F3 · derivative.exercise_date: 25% of the shares underlying this option vest on July 29, 2026, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2024 Equity Incentive Plan) to the Issuer on each such vesting date. Read SEC document
July 29, 2025 Filed Aug 1, 2025 01:05 UTC	ALUMIS INC. ALMS · Entity 4816	GrantStock Option (Right to Buy) · Derivative	662,000	$0.00 Strike: $3.95	$0.00	Disclosure SEC source: 0001415889-25-020801 · form4-07312025_090701.xml · derivative · entry 3 Babler Martin · CIK 0001435618 · Director · President, CEO and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 662,000 Underlying: Common Stock · 662,000 shares Expires 2035-07-28 F3 · derivative.exercise_date: 25% of the shares underlying this option vest on July 29, 2026, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2024 Equity Incentive Plan) to the Issuer on each such vesting date. Read SEC document
June 12, 2025 Filed Jun 13, 2025 20:13 UTC	Prelude Therapeutics Inc PRLD · Entity 5561	GrantDirector Stock Option (Right to Buy) · Derivative	38,000	$0.00 Strike: $1.04	$0.00	Disclosure SEC source: 0001562180-25-004786 · primarydocument.xml · derivative · entry 1 Babler Martin · CIK 0001435618 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,000 Underlying: Common Stock · 38,000 shares Expires 2035-06-11 F1 · derivative.exercise_date: The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date, such to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
April 01, 2025 Filed Apr 3, 2025 22:05 UTC	ALUMIS INC. ALMS · Entity 4816	PurchaseCommon Stock	15,650	$6.44	$100,732.79	Disclosure SEC source: 0001415889-25-010049 · form4-04032025_100402.xml · nonDerivative · entry 1 Babler Martin · CIK 0001435618 · Director · President, CEO and Chairman 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 106,454 F1 · price: Price reported is a weighted-average purchase price. The shares were purchased at prices ranging from $6.18 to $6.95. The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F2 · ownership.nature: Shares are held directly by Martin Babler revocable trust UAD October 25, 2006, for which Reporting Person serves as a trustee. Read SEC document
February 18, 2025 Filed Feb 20, 2025 23:30 UTC	ALUMIS INC. ALMS · Entity 4816	GrantStock Option (Right to Buy) · Derivative	523,000	$0.00 Strike: $5.06	$0.00	Disclosure SEC source: 0001415889-25-004936 · form4-02202025_060201.xml · derivative · entry 1 Babler Martin · CIK 0001435618 · Director · President, CEO and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 523,000 Underlying: Common Stock · 523,000 shares Expires 2035-02-17 F1 · derivative.exercise_date: 25% of the shares underlying this option vest on February 18, 2026, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document
February 03, 2025 Filed Feb 5, 2025 21:01 UTC	89bio, Inc. ETNB · Entity 73682	GrantStock Option (Right to Buy) · Derivative	56,400	$0.00 Strike: $9.60	$0.00	Disclosure SEC source: 0000950170-25-014434 · ownership.xml · derivative · entry 1 Babler Martin · CIK 0001435618 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,400 Underlying: Common Stock · 56,400 shares Expires 2035-02-03 F1 · derivative.exercise_date: This option represents a right to purchase a total of 56,400 shares of the Issuer's Common Stock, which will vest in full on February 1, 2026, subject to the Reporting Person's continued service to the Issuer through such date. Read SEC document
July 01, 2024 Filed Jul 1, 2024 20:35 UTC	ALUMIS INC. ALMS · Entity 4816	GrantStock Option (Right to Buy) · Derivative	245,989	$0.00 Strike: $13.33	$0.00	Disclosure SEC source: 0001415889-24-018589 · form4-07012024_080750.xml · derivative · entry 21 Babler Martin · CIK 0001435618 · Director · President, CEO and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 245,989 Underlying: Common Stock · 245,989 shares Expires 2034-06-05 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock. F11 · derivative.exercise_date: 25% of the shares underlying this option vest on June 6, 2025, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document
July 01, 2024 Filed Jul 1, 2024 20:35 UTC	ALUMIS INC. ALMS · Entity 4816	Disposition to issuerStock Option (Right to Buy) · Derivative	245,989	$0.00 Strike: $13.33	$0.00	Disclosure SEC source: 0001415889-24-018589 · form4-07012024_080750.xml · derivative · entry 20 Babler Martin · CIK 0001435618 · Director · President, CEO and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 245,989 shares Expires 2034-06-05 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock. F11 · derivative.exercise_date: 25% of the shares underlying this option vest on June 6, 2025, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document
July 01, 2024 Filed Jul 1, 2024 20:35 UTC	ALUMIS INC. ALMS · Entity 4816	GrantStock Option (Right to Buy) · Derivative	478,288	$0.00 Strike: $10.20	$0.00	Disclosure SEC source: 0001415889-24-018589 · form4-07012024_080750.xml · derivative · entry 19 Babler Martin · CIK 0001435618 · Director · President, CEO and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 478,288 Underlying: Common Stock · 478,288 shares Expires 2034-05-05 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock. F10 · derivative.exercise_date: The option vests in three equal installments, subject to the Issuer's satisfaction of certain performance criteria on each of May 6, 2028, May 6, 2029 and May 6, 2030, and subject to acceleration and the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document
July 01, 2024 Filed Jul 1, 2024 20:35 UTC	ALUMIS INC. ALMS · Entity 4816	Disposition to issuerStock Option (Right to Buy) · Derivative	478,288	$0.00 Strike: $10.20	$0.00	Disclosure SEC source: 0001415889-24-018589 · form4-07012024_080750.xml · derivative · entry 18 Babler Martin · CIK 0001435618 · Director · President, CEO and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 478,288 shares Expires 2034-05-05 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock. F10 · derivative.exercise_date: The option vests in three equal installments, subject to the Issuer's satisfaction of certain performance criteria on each of May 6, 2028, May 6, 2029 and May 6, 2030, and subject to acceleration and the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document
July 01, 2024 Filed Jul 1, 2024 20:35 UTC	ALUMIS INC. ALMS · Entity 4816	GrantStock Option (Right to Buy) · Derivative	241,210	$0.00 Strike: $8.84	$0.00	Disclosure SEC source: 0001415889-24-018589 · form4-07012024_080750.xml · derivative · entry 17 Babler Martin · CIK 0001435618 · Director · President, CEO and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 241,210 Underlying: Common Stock · 241,210 shares Expires 2034-03-28 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock. F9 · derivative.exercise_date: 25% of the shares underlying this option vest on March 29, 2025, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document
July 01, 2024 Filed Jul 1, 2024 20:35 UTC	ALUMIS INC. ALMS · Entity 4816	Disposition to issuerStock Option (Right to Buy) · Derivative	241,210	$0.00 Strike: $8.84	$0.00	Disclosure SEC source: 0001415889-24-018589 · form4-07012024_080750.xml · derivative · entry 16 Babler Martin · CIK 0001435618 · Director · President, CEO and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 241,210 shares Expires 2034-03-28 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock. F9 · derivative.exercise_date: 25% of the shares underlying this option vest on March 29, 2025, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document
July 01, 2024 Filed Jul 1, 2024 20:35 UTC	ALUMIS INC. ALMS · Entity 4816	GrantStock Option (Right to Buy) · Derivative	107,028	$0.00 Strike: $8.84	$0.00	Disclosure SEC source: 0001415889-24-018589 · form4-07012024_080750.xml · derivative · entry 15 Babler Martin · CIK 0001435618 · Director · President, CEO and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,028 Underlying: Common Stock · 107,028 shares Expires 2033-10-08 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock. F8 · derivative.exercise_date: 25% of the shares underlying this option vest on October 9, 2024, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document
July 01, 2024 Filed Jul 1, 2024 20:35 UTC	ALUMIS INC. ALMS · Entity 4816	Disposition to issuerStock Option (Right to Buy) · Derivative	107,028	$0.00 Strike: $8.84	$0.00	Disclosure SEC source: 0001415889-24-018589 · form4-07012024_080750.xml · derivative · entry 14 Babler Martin · CIK 0001435618 · Director · President, CEO and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 107,028 shares Expires 2033-10-08 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock. F8 · derivative.exercise_date: 25% of the shares underlying this option vest on October 9, 2024, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document
July 01, 2024 Filed Jul 1, 2024 20:35 UTC	ALUMIS INC. ALMS · Entity 4816	GrantStock Option (Right to Buy) · Derivative	263,101	$0.00 Strike: $8.84	$0.00	Disclosure SEC source: 0001415889-24-018589 · form4-07012024_080750.xml · derivative · entry 13 Babler Martin · CIK 0001435618 · Director · President, CEO and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 263,101 Underlying: Common Stock · 263,101 shares Expires 2033-06-22 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock. F7 · derivative.exercise_date: 25% of the shares underlying this option vested on May 22, 2024, and the remaining shares vest n equal monthly installments thereafter over the following 36 months, subject to acceleration and subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document
July 01, 2024 Filed Jul 1, 2024 20:35 UTC	ALUMIS INC. ALMS · Entity 4816	Disposition to issuerStock Option (Right to Buy) · Derivative	263,101	$0.00 Strike: $8.84	$0.00	Disclosure SEC source: 0001415889-24-018589 · form4-07012024_080750.xml · derivative · entry 12 Babler Martin · CIK 0001435618 · Director · President, CEO and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 263,101 shares Expires 2033-06-22 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock. F7 · derivative.exercise_date: 25% of the shares underlying this option vested on May 22, 2024, and the remaining shares vest n equal monthly installments thereafter over the following 36 months, subject to acceleration and subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document
July 01, 2024 Filed Jul 1, 2024 20:35 UTC	ALUMIS INC. ALMS · Entity 4816	GrantStock Option (Right to Buy) · Derivative	534,759	$0.00 Strike: $8.84	$0.00	Disclosure SEC source: 0001415889-24-018589 · form4-07012024_080750.xml · derivative · entry 11 Babler Martin · CIK 0001435618 · Director · President, CEO and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 534,759 Underlying: Common Stock · 534,759 shares Expires 2032-01-26 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock. F6 · derivative.exercise_date: 33% of the shares underlying this option vested on January 27, 2024, and the remaining shares vest in equal monthly installments thereafter over the following 48 months, subject to acceleration and subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document
July 01, 2024 Filed Jul 1, 2024 20:35 UTC	ALUMIS INC. ALMS · Entity 4816	Disposition to issuerStock Option (Right to Buy) · Derivative	534,759	$0.00 Strike: $8.84	$0.00	Disclosure SEC source: 0001415889-24-018589 · form4-07012024_080750.xml · derivative · entry 10 Babler Martin · CIK 0001435618 · Director · President, CEO and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 534,759 shares Expires 2032-01-26 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock. F6 · derivative.exercise_date: 33% of the shares underlying this option vested on January 27, 2024, and the remaining shares vest in equal monthly installments thereafter over the following 48 months, subject to acceleration and subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document
July 01, 2024 Filed Jul 1, 2024 20:35 UTC	ALUMIS INC. ALMS · Entity 4816	GrantStock Option (Right to Buy) · Derivative	106,951	$0.00 Strike: $8.84	$0.00	Disclosure SEC source: 0001415889-24-018589 · form4-07012024_080750.xml · derivative · entry 9 Babler Martin · CIK 0001435618 · Director · President, CEO and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,951 Underlying: Common Stock · 106,951 shares Expires 2032-01-26 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock. F5 · derivative.exercise_date: 25% of the shares underlying this option vested on January 27, 2023, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document
July 01, 2024 Filed Jul 1, 2024 20:35 UTC	ALUMIS INC. ALMS · Entity 4816	Disposition to issuerStock Option (Right to Buy) · Derivative	106,951	$0.00 Strike: $8.84	$0.00	Disclosure SEC source: 0001415889-24-018589 · form4-07012024_080750.xml · derivative · entry 8 Babler Martin · CIK 0001435618 · Director · President, CEO and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 106,951 shares Expires 2032-01-26 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock. F5 · derivative.exercise_date: 25% of the shares underlying this option vested on January 27, 2023, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document
July 01, 2024 Filed Jul 1, 2024 20:35 UTC	ALUMIS INC. ALMS · Entity 4816	GrantStock Option (Right to Buy) · Derivative	380,852	$0.00 Strike: $3.84	$0.00	Disclosure SEC source: 0001415889-24-018589 · form4-07012024_080750.xml · derivative · entry 7 Babler Martin · CIK 0001435618 · Director · President, CEO and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 380,852 Underlying: Common Stock · 380,852 shares Expires 2031-09-14 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock. F4 · derivative.exercise_date: 25% of the shares underlying this option vested on September 15, 2022, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and subject to the Reporting Person's continuous service to the Issuer on each such vesting date. This option was originally granted in the amount of 3,000,000 shares and was subsequently partially exercised for 1,219,513 shares on October 22, 2021. Read SEC document
July 01, 2024 Filed Jul 1, 2024 20:35 UTC	ALUMIS INC. ALMS · Entity 4816	Disposition to issuerStock Option (Right to Buy) · Derivative	380,852	$0.00 Strike: $3.84	$0.00	Disclosure SEC source: 0001415889-24-018589 · form4-07012024_080750.xml · derivative · entry 6 Babler Martin · CIK 0001435618 · Director · President, CEO and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 380,852 shares Expires 2031-09-14 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock. F4 · derivative.exercise_date: 25% of the shares underlying this option vested on September 15, 2022, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and subject to the Reporting Person's continuous service to the Issuer on each such vesting date. This option was originally granted in the amount of 3,000,000 shares and was subsequently partially exercised for 1,219,513 shares on October 22, 2021. Read SEC document
July 01, 2024 Filed Jul 1, 2024 20:35 UTC	ALUMIS INC. ALMS · Entity 4816	GrantStock Option (Right to Buy) · Derivative	21,390	$0.00 Strike: $16.00	$0.00	Disclosure SEC source: 0001415889-24-018589 · form4-07012024_080750.xml · derivative · entry 5 Babler Martin · CIK 0001435618 · Director · President, CEO and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,390 Underlying: Common Stock · 21,390 shares Expires 2034-06-26 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock. F3 · derivative.exercise_date: 25% of the shares underlying this option vest on June 21, 2025, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document
July 01, 2024 Filed Jul 1, 2024 20:35 UTC	ALUMIS INC. ALMS · Entity 4816	Disposition to issuerStock Option (Right to Buy) · Derivative	21,390	$0.00 Strike: $16.00	$0.00	Disclosure SEC source: 0001415889-24-018589 · form4-07012024_080750.xml · derivative · entry 4 Babler Martin · CIK 0001435618 · Director · President, CEO and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 21,390 shares Expires 2034-06-26 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock. F3 · derivative.exercise_date: 25% of the shares underlying this option vest on June 21, 2025, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document
July 01, 2024 Filed Jul 1, 2024 20:35 UTC	ALUMIS INC. ALMS · Entity 4816	GrantCommon Stock	90,804	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-24-018589 · form4-07012024_080750.xml · nonDerivative · entry 2 Babler Martin · CIK 0001435618 · Director · President, CEO and Chairman 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 90,804 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock. F1 · price: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock. F2 · ownership.nature: Shares are held directly by Martin Babler revocable trust UAD October 25, 2006, for which Reporting Person serves as a trustee. Read SEC document
July 01, 2024 Filed Jul 1, 2024 20:35 UTC	ALUMIS INC. ALMS · Entity 4816	Disposition to issuerClass A Common Stock	90,804	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-24-018589 · form4-07012024_080750.xml · nonDerivative · entry 1 Babler Martin · CIK 0001435618 · Director · President, CEO and Chairman 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 0 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock. F1 · price: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock. F2 · ownership.nature: Shares are held directly by Martin Babler revocable trust UAD October 25, 2006, for which Reporting Person serves as a trustee. Read SEC document
June 27, 2024 Filed Jul 1, 2024 20:35 UTC	ALUMIS INC. ALMS · Entity 4816	GrantStock Option (Right to Buy) · Derivative	21,390	$0.00 Strike: $16.00	$0.00	Disclosure SEC source: 0001415889-24-018589 · form4-07012024_080750.xml · derivative · entry 3 Babler Martin · CIK 0001435618 · Director · President, CEO and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,390 Underlying: Class A Common Stock · 21,390 shares Expires 2034-06-26 F3 · derivative.exercise_date: 25% of the shares underlying this option vest on June 21, 2025, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document
June 14, 2024 Filed Jun 18, 2024 20:11 UTC	Prelude Therapeutics Inc PRLD · Entity 5561	GrantDirector Stock Option (Right to Buy) · Derivative	23,500	$0.00 Strike: $3.90	$0.00	Disclosure SEC source: 0001562180-24-005159 · primarydocument.xml · derivative · entry 1 Babler Martin · CIK 0001435618 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,500 Underlying: Common Stock · 23,500 shares Expires 2034-06-13 F1 · derivative.exercise_date: The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
May 02, 2024 Filed May 3, 2024 20:01 UTC	89bio, Inc. ETNB · Entity 73682	GrantStock Option (Right to Buy) · Derivative	67,700	$0.00 Strike: $8.86	$0.00	Disclosure SEC source: 0000950170-24-052857 · ownership.xml · derivative · entry 1 Babler Martin · CIK 0001435618 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,700 Underlying: Common Stock · 67,700 shares Expires 2034-05-02 F1 · derivative.exercise_date: This option represents a right to purchase a total of 67,700 shares of the Issuer's Common Stock, which vests in equal installments on April 13, 2025, April 13, 2026 and April 13, 2027, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document
June 16, 2023 Filed Jun 21, 2023 20:11 UTC	Prelude Therapeutics Inc PRLD · Entity 5561	GrantDirector Stock Option (Right to Buy) · Derivative	23,500	$0.00 Strike: $5.56	$0.00	Disclosure SEC source: 0001209191-23-038770 · doc4.xml · derivative · entry 1 Babler Martin · CIK 0001435618 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,500 Underlying: Common Stock · 23,500 shares Expires 2033-06-15 F1 · derivative.exercise_date: The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
June 08, 2023 Filed Jun 9, 2023 20:24 UTC	Neurogene Inc. NLTX · Entity 5160	GrantStock Option (Right to Buy) · Derivative	25,000	$0.00 Strike: $0.79	$0.00	Disclosure SEC source: 0001209191-23-035853 · doc4.xml · derivative · entry 1 Babler Martin · CIK 0001435618 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-06-07 F1 · derivative.exercise_date: The option vests as to 1/12 of the total shares monthly beginning July 8, 2023 until the option is fully vested on June 8, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
June 17, 2022 Filed Jun 22, 2022 20:13 UTC	Prelude Therapeutics Inc PRLD · Entity 5561	GrantDirector Stock Option (Right to Buy) · Derivative	31,293	$0.00 Strike: $4.74	$0.00	Disclosure SEC source: 0001562180-22-005296 · primarydocument.xml · derivative · entry 1 Babler Martin · CIK 0001435618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,293 Underlying: Common Stock · 31,293 shares Expires 2032-06-16 F1 · derivative.exercise_date: The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date, such to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
May 12, 2022 Filed May 16, 2022 22:22 UTC	Neurogene Inc. NLTX · Entity 5160	GrantStock Option (Right to Buy) · Derivative	25,000	$0.00 Strike: $1.07	$0.00	Disclosure SEC source: 0001209191-22-029321 · doc4.xml · derivative · entry 1 Babler Martin · CIK 0001435618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-05-11 F1 · derivative.exercise_date: The option vests as to 1/12 of the total shares monthly beginning June 12, 2022 until the option is fully vested on May 12, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
July 19, 2021 Filed Jul 21, 2021 00:30 UTC	Prelude Therapeutics Inc PRLD · Entity 5561	GrantEmployee Stock Option (Right to Buy) · Derivative	36,400	$0.00 Strike: $31.37	$0.00	Disclosure SEC source: 0001209191-21-047500 · doc4.xml · derivative · entry 1 Babler Martin · CIK 0001435618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,400 Underlying: Common Stock · 36,400 shares Expires 2031-07-18 F1 · derivative.exercise_date: The stock option vested as to 1/36 of the total shares monthly beginning on August 19, 2021 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
May 11, 2021 Filed May 13, 2021 21:36 UTC	Neurogene Inc. NLTX · Entity 5160	GrantStock Option (Right to Buy) · Derivative	25,000	$0.00 Strike: $11.40	$0.00	Disclosure SEC source: 0001209191-21-032397 · doc4.xml · derivative · entry 1 Babler Martin · CIK 0001435618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-05-10 F1 · derivative.exercise_date: The option vests as to 1/12 of the total shares monthly beginning June 11, 2021 until the option is fully vested on May 11, 2022, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
September 28, 2020 Filed Sep 28, 2020 21:07 UTC	Principia Biopharma Inc. PRNB · Entity 146423	Disposition to issuerEmployee Stock Option (right to buy) · Derivative	200,000	Not disclosed Strike: $67.31	Not disclosed	Disclosure SEC source: 0001209191-20-052222 · doc4.xml · derivative · entry 13 Babler Martin · CIK 0001435618 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 200,000 shares Expires 2030-03-04 F6 · kind: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. F6 · price: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. F6 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. Read SEC document
September 28, 2020 Filed Sep 28, 2020 21:07 UTC	Principia Biopharma Inc. PRNB · Entity 146423	Disposition to issuerEmployee Stock Option (right to buy) · Derivative	155,000	Not disclosed Strike: $35.42	Not disclosed	Disclosure SEC source: 0001209191-20-052222 · doc4.xml · derivative · entry 12 Babler Martin · CIK 0001435618 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 155,000 shares Expires 2029-02-28 F6 · kind: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. F6 · price: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. F6 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. Read SEC document
September 28, 2020 Filed Sep 28, 2020 21:07 UTC	Principia Biopharma Inc. PRNB · Entity 146423	Disposition to issuerEmployee Stock Option (right to buy) · Derivative	187,144	Not disclosed Strike: $11.35	Not disclosed	Disclosure SEC source: 0001209191-20-052222 · doc4.xml · derivative · entry 11 Babler Martin · CIK 0001435618 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 187,144 shares Expires 2028-08-23 F6 · kind: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. F6 · price: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. F6 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. Read SEC document
September 28, 2020 Filed Sep 28, 2020 21:07 UTC	Principia Biopharma Inc. PRNB · Entity 146423	Disposition to issuerEmployee Stock Option (right to buy) · Derivative	115,590	Not disclosed Strike: $7.27	Not disclosed	Disclosure SEC source: 0001209191-20-052222 · doc4.xml · derivative · entry 10 Babler Martin · CIK 0001435618 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 115,590 shares Expires 2027-12-13 F6 · kind: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. F6 · price: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. F6 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. Read SEC document
September 28, 2020 Filed Sep 28, 2020 21:07 UTC	Principia Biopharma Inc. PRNB · Entity 146423	Disposition to issuerEmployee Stock Option (right to buy) · Derivative	60,546	Not disclosed Strike: $5.00	Not disclosed	Disclosure SEC source: 0001209191-20-052222 · doc4.xml · derivative · entry 9 Babler Martin · CIK 0001435618 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,546 shares Expires 2025-07-20 F6 · kind: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. F6 · price: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. F6 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. Read SEC document
September 28, 2020 Filed Sep 28, 2020 21:07 UTC	Principia Biopharma Inc. PRNB · Entity 146423	Disposition to issuerEmployee Stock Option (right to buy) · Derivative	83,004	Not disclosed Strike: $4.72	Not disclosed	Disclosure SEC source: 0001209191-20-052222 · doc4.xml · derivative · entry 8 Babler Martin · CIK 0001435618 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 83,004 shares Expires 2024-12-25 F6 · kind: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. F6 · price: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. F6 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. Read SEC document
September 28, 2020 Filed Sep 28, 2020 21:07 UTC	Principia Biopharma Inc. PRNB · Entity 146423	Disposition to issuerEmployee Stock Option (right to buy) · Derivative	110,085	Not disclosed Strike: $3.18	Not disclosed	Disclosure SEC source: 0001209191-20-052222 · doc4.xml · derivative · entry 7 Babler Martin · CIK 0001435618 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 110,085 shares Expires 2024-06-26 F6 · kind: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. F6 · price: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. F6 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. Read SEC document
September 28, 2020 Filed Sep 28, 2020 21:07 UTC	Principia Biopharma Inc. PRNB · Entity 146423	Disposition to issuerEmployee Stock Option (right to buy) · Derivative	85,728	Not disclosed Strike: $3.00	Not disclosed	Disclosure SEC source: 0001209191-20-052222 · doc4.xml · derivative · entry 6 Babler Martin · CIK 0001435618 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 85,728 shares Expires 2023-10-23 F6 · kind: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. F6 · price: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. F6 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. Read SEC document
September 28, 2020 Filed Sep 28, 2020 21:07 UTC	Principia Biopharma Inc. PRNB · Entity 146423	Disposition to issuerEmployee Stock Option (right to buy) · Derivative	50,795	Not disclosed Strike: $1.91	Not disclosed	Disclosure SEC source: 0001209191-20-052222 · doc4.xml · derivative · entry 5 Babler Martin · CIK 0001435618 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,795 shares Expires 2022-07-02 F6 · kind: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. F6 · price: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. F6 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.